Skip to main content

Patients Discovering Breast

Web Exclusives - Breast Cancer

SAN ANTONIO—A rapidly growing, nationwide clinical trial matching service that is user-friendly for patients is enabling more patients to learn about and enroll in clinical trials, said Ellie Cohen, PhD, the program's director. Cohen described the success of her program at the 33rd annual San Antonio Breast Cancer Symposium. is a web-based clinical trials matching service designed to empower patients and increase trial participation. Patients find trials looking for participants with their medical situation and connect with research sites. The site was launched in 2008 by the Carol Franc Buck Breast Care Center at the University of California San Francisco National Center of Excellence in Women's Health in collaboration with Quantum Leap Healthcare Collaborative.

"Thousands of patients have adopted and they use it to monitor trial opportunities. Our portfolio of breast cancer trials is diverse and growing," Cohen said. "The purpose is to help patients who might not hear about trials from their doctors."

The total number of visitors to date is more than 35,000. Of patients who start a health history, 61% complete it and are matched to trials and, of this group, 41% find at least one trial interesting enough to view the site contact information. Cohen does not have information as to how many patients actually enroll, and the numbers reflect only users who complete the application in one visit.

What The Site Offers

The online forms are customized depending on whether the user is recently diagnosed, managing metastatic disease, or has completed treatment. Women can choose whether to use the service anonymously or to save their health history by providing an e-mail address. They are matched with trials appropriate for their disease and can view research site information, including the closest research site and distance from the patient's home.

The trial portfolio includes 450 trials, including 275 treatment trials, 84 psychosocial/supportive trials, 32 evaluating diagnosis/screening, 22 assessing preventive approaches, and 37 in other categories.

"Trials are for all patients," Cohen stressed. "There is a big myth that they are only for patients who run out of options, but 40% of our trials are in the neoadjuvant and adjuvant setting. Wherever you are on the cancer journey, there is an opportunity to participate in a clinical trial. We want patients to consider trials as a routine option for their breast cancer care."

Users can share their history with participating research sites through the SecureConnnect message service. This enables the first screening interview to be simplified as well as efficient, and the user can leave a personal message for the research site, such as, "I don't have health insurance. Can I still enroll?"

The website now also has a weekly trial alert service that informs users when newly listed trials match their health history. The service has more than 1600 subscribers, and 85% of users who save a history sign up for these alerts, she said.

"The trial alert service has been responsible for a 68% increase in users," according to Cohen. "It's prompting users to log in and view newly posted trials."

During the first year, there were 4587 returning users and this increased to 7736 in year 2 after the trial alert service was launched.

Who is Using

By disease stage, 440 of 1814 users (who saved their history) were stage 0 to III and recently diagnosed; 746 had completed treatment for stage 0 to III disease; and 628 were living with metastatic disease.

Most current users are 50 to 69 years old, with women aged 40 to 49 a close second. Most users have been white (non-Hispanic) women with some college education. Fewer than 10% have no more than a high school degree. "Our early adopters are educated and white, but we hope to change this through outreach to underserved populations," Cohen said.

Related Items
The Pharmacist and Patients With HER2-Positive or HER2-Low Metastatic Breast Cancer: Navigating the Treatment Landscape
The Pharmacist and Patients With HER2-Positive or HER2-Low Metastatic Breast Cancer: Navigating the Treatment Landscape published on January 11, 2024 in Breast Cancer
Ovarian Function Suppression in Premenopausal Women with HR+ Breast Cancer
Emily M. Beard, RN, BSN, OCN, CBCN, Abbey J. Kaler, MS, APRN, FNP-C, Mohammed A. Jaloudi, MD
Best Practices in Ovarian Function Suppression in Breast Cancer published on December 21, 2023 in Breast Cancer
Enhertu Received Regular FDA Approval for Patients with Unresectable or Metastatic Breast Cancer
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Breast Cancer
Pembrolizumab plus Chemotherapy for Neoadjuvant and Adjuvant Therapy in Early Triple-Negative Breast Cancer: KEYNOTE-522
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in From the Literature, Breast Cancer, Checkpoint Inhibitors
Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Breast Cancer
Evaluating Adverse Events in Patients with Breast Cancer and HIV Infection Receiving Concomitant Antiretroviral Therapy and Chemotherapy with Curative Intent
Donyika Joseph, PharmD, BCOP, Farnaz Foolad, PharmD, BCPS, Neelam K. Patel, PharmD, BCOP, Meghan Karuturi, MD, MSc, Jaime Kaushik, PharmD, BCOP
JHOP - April 2022 Vol 12, No 2 published on May 2, 2022 in Original Article, Adverse Events, Breast Cancer, Infections
Advances in Breast Cancer Treatments: Are We Extending Patients’ Survival?
Meg Barbor, MPH
JHOP - June 2019 Vol 9, No 2 published on April 28, 2022 in HOPA Highlights, Breast Cancer
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Time to Treatment Initiation and Outcomes for Patients with Nonmetastatic Breast Cancer Before and During the COVID-19 Pandemic at Community Cancer Centers
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Spontaneous Tumor Lysis Syndrome in a Patient with Stage IV HER2-Positive Breast Cancer: Case Report
Blake T. Robbins, PharmD, MBA , Alexander M. Kreimer, PharmD, BCPS , Reema A. Patel, MD, Allison R. Butts, PharmD, BCOP
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Case Reports, Tumor Lysis Syndrome, Breast Cancer